FDA Approved: SYMLINPEN — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for SYMLINPEN (pramlintide acetate) from AstraZeneca Pharmaceuticals LP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• SYMLINPEN (PRAMLINTIDE ACETATE)

Snippet

SUPPL AP for SYMLINPEN (PRAMLINTIDE ACETATE)